Latest Regulatory News

Genesis Energy reported a robust FY25 with a 14% rise in normalised EBITDAF and a 29% jump in net profit, driven by strategic portfolio flexibility amid volatile energy markets. The company accelerated its Gen35 strategy, including key renewable projects and long-term capacity contracts to bolster New Zealand’s energy security.

Metals X Limited reported a robust half-year to June 2025 with profit after tax soaring 256% to $52.9 million, driven by higher tin sales and prices from its Renison joint venture. The company also progressed key projects and deepened strategic investments while reinforcing its ESG and safety frameworks.

Unibail-Rodamco-Westfield has requested suspension of its securities from the ASX, marking the first step toward its official delisting. This move signals a significant shift for investors and the commercial property sector.

Actinogen Medical reports steady progress in its Alzheimer’s and depression drug trials, backed by strong funding and strategic commercial planning. Key interim data from the pivotal XanaMIA trial is expected early next year.

Actinogen Medical reported a $14.7 million net loss for FY25 while progressing its lead drug Xanamem through pivotal Alzheimer’s and depression trials, with interim results expected in January 2026. The company has secured funding through mid-2026 and is preparing for commercialization.

Felix Group Holdings Ltd has announced a $1 million share purchase plan, offering eligible shareholders the chance to buy shares at $0.21 each starting 26 August 2025.

K&S Corporation reported a 9% decline in underlying profit before tax for FY2025, alongside a 9.7% drop in revenue, as it invests heavily in property and terminal upgrades while navigating safety regulatory pressures.

Platinum Asia Investments Limited has refined the payout figure for its final special dividend, enhancing precision for shareholders ahead of the September payment date.

Polynovo Limited reported a robust 23.3% increase in total revenue for FY25, driven by strong commercial sales growth across the US and international markets. The company is advancing its FDA PMA submission and expanding its global footprint amid strategic product development.

PolyNovo Limited reported a robust 28.9% increase in group sales to A$118.6 million for FY25, alongside a 151% surge in net profit after tax to A$13.2 million, driven by strong U.S. growth and key regulatory approvals.

Cyclone Metals Limited's shares have been suspended from trading on the ASX due to a non-compliant announcement, leaving investors in limbo until a suitable update is provided.

Ambertech Limited reported a 6% increase in revenue to $101.2 million for FY25, yet net profit after tax fell sharply by 38% to $0.84 million amid inflationary pressures and increased costs. The company declared a fully franked final dividend and remains optimistic about FY26.